Posted by Michael Wonder on 01 Sep 2023
Hugel resubmits BLA for its botulinum toxin, Letybo to the US FDA
1 September 2023 - Expected to obtain the US FDA's approval in the first quarter of 2024.
Hugel announced that the company resubmitted the biologics license application for its botulinum toxin, Letybo (letibotulinumtoxinA) on 31 August (local time), for the indication of glabellar (frown) lines to the US FDA.
